Product Description
Mechanisms of Action: SNR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Belgium | Czech | India | Ireland | Korea | Luxembourg | Malta | Netherlands | New Zealand | Pakistan | Portugal | Saudi Arabia | Singapore | Slovakia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ministry of Infrastructure and the Environment
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Depressive Disorder
Phase 3: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| INTENSIFY MDD | P3 |
Unknown Status |
Depressive Disorder, Major |
2026-06-30 |
|
| T/IM-F/Psych/15/20 | N/A |
Completed |
Depressive Disorder |
2017-12-31 |
|
| 2013-004936-31 | P4 |
Completed |
Depressive Disorder |
2016-05-28 |